Fingolimod is a derivative of the naturally occurring immunosuppressive substance myriocin, with structural similarity to sphingosine, a ubiquitous sphingolipid. It acts as an immunomodulator interfering with the egress of T and B lymphocytes from secondary lymph organs, which results in lymphopenia. A phase II study in patients with multiple scerosis showed a significant reduction in annual relapse rate and lesions in magnetic resonance imaging with an acceptable rate of side effects. An advantage of fingolimod compared to interferon beta, glatirameracetate and natalizumab is its oral availability. Definitive assessment of the compound has to await the results of trials currently being performed.
